Patients File Lawsuits Against GLP-1 Drug Makers for Vision Loss

WHO:

NBC News - A woman who used semaglutide and lost vision is among those suing the makers of GLP-1 weight-loss drugs.

NBC News - Hundreds of Americans are suing GLP-1 drugmakers Novo Nordisk and Eli Lilly.

Al Jazeera - Dozens of patients are suing GLP-1 drug manufacturers.

ABC News - The lawsuits involve users of GLP-1 medications.

WHAT:

NBC News - The lawsuits now involve claims from over 600 patients alleging vision loss after using GLP-1 medications, an increase from the previously reported 500 patients.

NBC News - A woman involved in the lawsuits stated, “I never thought a medication meant to help me would take away my sight.”

NBC News - The lawsuits involve claims from over 500 patients alleging vision loss after using GLP-1 medications, with some patients reporting that their vision loss occurred within days of starting the treatment.

NBC News - The lawsuits allege that the drug companies did not provide adequate warnings about the potential for vision loss associated with their medications.

NewsNation - The lawsuits allege that patients experienced "acute vision loss" after using GLP-1 medications, with some patients reporting that their vision loss occurred within days of starting the treatment.

NBC News - The lawsuits are being filed as class-action suits against the drug companies, with claims from over 500 patients alleging vision loss after using GLP-1 medications.

NewsNation - The lawsuits allege that patients experienced sudden vision loss, which they claim occurred after using GLP-1 medications.

NBC News - The lawsuits allege that patients experienced a rare type of vision loss known as "acute vision loss" after using GLP-1 medications.

NBC News - The lawsuits involve claims from hundreds of patients alleging that they experienced vision loss after using GLP-1 medications.

NBC News - The lawsuits allege that the companies did not adequately warn patients about the potential danger of vision loss.

Al Jazeera - Patients allege that the GLP-1 drugs caused vision loss.

ABC News - A rare type of vision loss is being reported among users of GLP-1 medications.

WHERE:

Al Jazeera - The lawsuits are being filed in various jurisdictions across the United States.

WHEN:

ABC News - The lawsuits are expected to proceed in court in the coming months.

WHY:

Al Jazeera - Patients claim that the drug manufacturers failed to adequately warn them about the risks associated with the medications.

HOW:

NBC News - Eli Lilly has reiterated that it is committed to transparency and is actively reviewing the claims made in the lawsuits, emphasizing that it has a robust safety monitoring system in place.

NBC News - Eli Lilly stated that it is committed to transparency and is reviewing the claims made in the lawsuits, emphasizing that it has a robust safety monitoring system in place.

NBC News - Eli Lilly stated that it is reviewing the claims made in the lawsuits and emphasized that “patient safety” is its “top priority.”

NBC News - Eli Lilly has stated that it is committed to transparency and is reviewing the claims made in the lawsuits.

NBC News - Novo Nordisk has stated that they are “vigorously” fighting the lawsuits, asserting that the claims are “without merit.”

NBC News - Novo Nordisk states they are “vigorously” fighting the lawsuits, claiming they are “without merit,” while Eli Lilly emphasizes that “patient safety” is its “top priority.”

ABC News - The lawsuits are being filed as class-action suits against the drug companies.

(UPDATED September 23, 2026 21:57 UTC)

Lawsuits now involve claims from over 600 patients alleging vision loss after using GLP-1 medications, an increase from the previously reported 500. One woman involved in the lawsuits expressed her shock, stating, “I never thought a medication meant to help me would take away my sight.” In response, Eli Lilly has reiterated its commitment to transparency and is actively reviewing the claims, emphasizing that it has a robust safety monitoring system in place.

(UPDATED September 23, 2026 18:58 UTC)

Over 500 patients have filed lawsuits claiming vision loss after using GLP-1 medications, with some reporting that their vision issues began just days after starting treatment. In response, Eli Lilly has stated its commitment to transparency and is currently reviewing the claims, highlighting its robust safety monitoring system. The company aims to address these serious allegations while ensuring patient safety remains a top priority.

(UPDATED September 23, 2026 16:58 UTC)

A woman who experienced vision loss after using semaglutide is among those suing the manufacturers of GLP-1 weight-loss drugs. The lawsuits claim that these drug companies failed to provide sufficient warnings regarding the risk of vision loss linked to their medications. This legal action highlights growing concerns about the safety and transparency of weight-loss treatments.

(UPDATED September 23, 2026 15:58 UTC)

Lawsuits are being filed as class-action suits against drug companies, with over 500 patients alleging acute vision loss after using GLP-1 medications, and some reporting this troubling side effect just days after starting treatment. Eli Lilly has responded by stating its commitment to transparency and is currently reviewing the claims, while emphasizing that it has a robust safety monitoring system in place. As these legal actions unfold, the focus remains on the experiences of those affected by these medications.

(UPDATED September 23, 2026 13:03 UTC)

Lawsuits have been filed alleging that patients experienced sudden vision loss after using GLP-1 medications. In response, Eli Lilly has stated that it is reviewing the claims and emphasized that patient safety is its top priority. The company is taking these allegations seriously as it continues to investigate the matter.

(UPDATED September 23, 2026 07:11 UTC)

Lawsuits have been filed alleging that patients experienced a rare type of vision loss known as "acute vision loss" after using GLP-1 medications. In response, Eli Lilly has expressed its commitment to transparency and is currently reviewing the claims made in these lawsuits. The situation continues to develop as more information becomes available.

(UPDATED September 23, 2026 01:20 UTC)

Hundreds of patients are filing lawsuits claiming they experienced vision loss after using GLP-1 medications. In response, Novo Nordisk has announced that they are “vigorously” fighting these lawsuits, insisting that the claims are “without merit.” The situation continues to develop as the legal battle unfolds.

(UPDATED September 22, 2026 22:59 UTC)

Hundreds of Americans are suing GLP-1 drugmakers Novo Nordisk and Eli Lilly, alleging that the companies failed to adequately warn patients about the potential risk of vision loss. In response, Novo Nordisk has stated they are “vigorously” fighting the lawsuits, asserting that the claims are “without merit,” while Eli Lilly emphasizes that “patient safety” is its “top priority.” The legal battle continues as both companies prepare to defend their practices in court.

(UPDATED September 22, 2026 22:04 UTC)

Dozens of patients are suing manufacturers of GLP-1 medications, alleging that these drugs caused a rare type of vision loss. The lawsuits are being filed as class-action suits in various jurisdictions across the United States, with proceedings expected to move forward in the coming months. Patients claim that the drug companies failed to adequately warn them about the associated risks of these medications.